palmoplantar pustulosis

AnaptysBio Inc (NASDAQ: ANAB) reports disappointing top-line data from its Phase 2 (POPLAR) trial of imsidolimab for palmoplantar pustulosis (PPP). The study failed to meet its primary endpoint of improvement on disease severity index from baseline at week 16,...